12.08.2014

Public production of serum with IgY technology against snakebite poisons and bacterial toxins

The project will be developed through funding from the National Agency for Scientific and Technological Promotion, through the Argentinean Sector Fund.

Lazovski, Anglesio, Ladenheim, Mac Donald and the legal representative of the consortium during the signing of the contract.

Lazovski, Anglesio, Ladenheim, Mac Donald and the legal representative of the consortium during the signing of the contract.

The National Agency for Scientific and Technological Promotion under the Ministry of Science, Technology and Productive Innovation awarded more than $27 million to fund a development project of heterologous serums based on the IgY technology, related to egg yolk antibodies to treat poisonings and intoxications. The signing ceremony of the agreement was led by the Secretary of Planning and Policy in Science, Technology and Productive Innovation, Ruth Ladenheim, together with the director of the Argentinean Sector Fund (FONARSEC) of the Agency, Isabel Mac Donald and the head of ANLIS, Dr. Jaime Lazovski, and the president of INTA, Francisco Anglesio also attended the meeting.

During the meeting, Ladenheim said “this project aims to strengthen the national drug production oriented to important public health needs” and he added that “it relates to the Plan Nacional Argentina Innovadora 2020 which states, inter alia, the importance of promoting projects aimed at solving the health needs of the population”. The Secretary also praised the joint effort with the Ministry of Health in identifying priorities.

Meanwhile, Mac Donald said that: "this initiative has a very high component of research and development which deserves to be highlighted" and he added that "we hope to have an impact not only at national level but at the level of Mercosur and contribute to strengthening public laboratories".  

The aim of the project is the production of antiserum in a pilot scale based in IgY egg yolk antibodies against bacterial toxins and snakebite poisons of interest in the field of national and regional public health as a complement or replacement of the current heterologous antivenins produced in horses. The initiative will be carried out by a public-public consortium composed of the National Institute of Agricultural Technology (INTA), through the Center for Research in Veterinary and Agricultural (CICVyA-INTA) and the National Administration of Laboratories and Health Institutes Carlos Malbrán”(ANLIS), through its National Institute of Biological Production (INPB-ANLIS) and the National Center for Biologics Quality Control (CNCCB-ANLIS). These institutions shall provide almost $19 million as counterpart to achieve the project wherein more than $46 million will be invested in a 3-year term.

The initiative was presented in the framework of the Sector Technological Innovation Fund of Health 2013 - Public Drug Production managed by the FONARSEC.

SEARCH
News
RELATED INFORMATION
Area
National Agency for Science and Technology Promotion
Photos
  • Lazovski, Anglesio, Ladenheim, Mac Donald and the legal representative of the consortium during the signing of the contract.
  • Lazovski, Anglesio, Ladenheim, Mac Donald and the legal representative of the consortium during the signing of the contract.
  • Lazovski, Anglesio, Ladenheim, Mac Donald and the legal representative of the consortium during the signing of the contract.
Image of
Lazovski, Anglesio, Ladenheim, Mac Donald and the legal representative of the consortium during the signing of the contract.

Lazovski, Anglesio, Ladenheim, Mac Donald and the legal representative of the consortium during the signing of the contract.

Video
Video of
Documents